Australia markets open in 5 hours 35 minutes

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.10-0.17 (-3.23%)
As of 02:24PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 599.64M
Enterprise value 388.00M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.16
Price/book (mrq)1.63
Enterprise value/revenue 6.11
Enterprise value/EBITDA -2.25

Trading information

Stock price history

Beta (5Y monthly) 1.68
52-week change 3-12.17%
S&P500 52-week change 321.61%
52-week high 38.83
52-week low 31.63
50-day moving average 36.90
200-day moving average 34.09

Share statistics

Avg vol (3-month) 32.82M
Avg vol (10-day) 31.99M
Shares outstanding 5113.78M
Implied shares outstanding 6113.78M
Float 880.71M
% held by insiders 11.47%
% held by institutions 191.82%
Shares short (28 Mar 2024) 416.49M
Short ratio (28 Mar 2024) 45.95
Short % of float (28 Mar 2024) 417.90%
Short % of shares outstanding (28 Mar 2024) 414.49%
Shares short (prior month 29 Feb 2024) 413.49M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin -253.30%
Operating margin (ttm)-2,098.75%

Management effectiveness

Return on assets (ttm)-18.32%
Return on equity (ttm)-37.76%

Income statement

Revenue (ttm)63.53M
Revenue per share (ttm)0.65
Quarterly revenue growth (yoy)-96.20%
Gross profit (ttm)N/A
EBITDA -159.33M
Net income avi to common (ttm)-160.93M
Diluted EPS (ttm)-1.64
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)315.18M
Total cash per share (mrq)3.18
Total debt (mrq)103.54M
Total debt/equity (mrq)28.10%
Current ratio (mrq)8.48
Book value per share (mrq)3.73

Cash flow statement

Operating cash flow (ttm)-132.26M
Levered free cash flow (ttm)-74.25M